
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
市場タイムラインとシグナルフィードを解放
過去 90 日間に 6 件のシグナル。
この企業が各市場へ参入した順序 — 古い順から新しい順へ
Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO
Director, Medical Affairs
登録してシグナルフィードをすべて表示
Alnylam Pharmaceuticals の海外展開を競合と比較
バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
Alnylam Pharmaceuticals自社 | 5 | 2 | 0% | 6 | 33 |
Scientist, Process Sciences
求人を見るCambridge, MA · 先週
Medical Science Liaison, Lead (Associate Director) - Italy
求人を見るGreater Rome Metropolitan Area · 先週
Medical Science Liaison, Lead (Associate Director) - Italy
求人を見るMilan, Lombardy, Italy · 先週
実施中のキャンペーンはありません
この企業をフォローして、変化があり次第通知を受け取るにはサインアップしてください。
Alnylam Pharmaceuticalsは、医薬品Amvuttraのマーケティング主張に関してFDAの審査を受けており、規制遵守の懸念が高まっている。
ナスダックは2025年12月22日付けでナスダック100指数に6社を追加すると発表。Alnylam PharmaceuticalsとFerrovial SEを含む。
ナスダック100指数は1.58%上昇し、半導体株が急反発。マイクロンが9.87%上昇を主導し、KLAC、AMAT、ASMLなどの半導体装置メーカーも大幅高。
認証済みメールと直通電話を解放
無料 · カード不要
Alnylam Pharmaceuticals の事業、市場、成長シグナルに関する簡潔な回答。

© 2026 Pubrio. 無断転載を禁じます。